SCHEMBL7175197

SCHEMBL7175197

COc1cc(OC)c(C(=O)[P](=O)c2ccccc2C(=O)c2c(C(C)(C)C)cc(C(C)(C)C)cc2C(C)(C)C)c(OC)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
LPAR1 Q92633 1/20 0.38
KMT2A Q03164 4/20 0.34
CYP3A4 P08684 2/20 0.34
TP53 P04637 1/20 0.34
ATM Q13315 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
NR1H4 Q96RI1 2/20 0.32
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32
NPC1 O15118 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185498 0.92 MAPT (0.39) MAPTNPSR1LPAR1KMT2AHSD17B10
SCHEMBL7182814 0.83 LMNA (0.40) MAPTNPSR1KMT2AATMMEN1
SCHEMBL7188977 0.83 MAPT (0.41) MAPTKMT2ACYP3A4TP53ATM
SCHEMBL7181486 0.82 TP53 (0.36) KMT2ACYP3A4TP53SMN1; SMN2
SCHEMBL7181292 0.82 ALDH1A1 (0.38) MAPTKMT2ACYP3A4TP53ATM
SCHEMBL7182631 0.81 RORB (0.37) MAPTNPSR1CYP3A4ATMALDH1A1
SCHEMBL7185600 0.81 SMN1; SMN2 (0.34) CYP3A4SMN1; SMN2
SCHEMBL7189850 0.81 MEN1 (0.34) KMT2ATP53MEN1SMN1; SMN2
SCHEMBL7736110 0.81 ALDH1A1 (0.43) MAPTKMT2ACYP3A4TP53ATM
SCHEMBL7182505 0.81 KMT2A (0.40) MAPTKMT2ACYP3A4TP53ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885NPSR1 2669/4885LPAR1 499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.